495 related articles for article (PubMed ID: 21427284)
21. [Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients].
Smith D; Bosacki C; Merrouche Y
Bull Cancer; 2009 Dec; 96 Suppl():S31-40. PubMed ID: 20034868
[TBL] [Abstract][Full Text] [Related]
22. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
23. Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer.
Saadeh CE; Lee HS
Ann Pharmacother; 2007 Apr; 41(4):606-13. PubMed ID: 17355997
[TBL] [Abstract][Full Text] [Related]
24. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.
Misale S; Di Nicolantonio F; Sartore-Bianchi A; Siena S; Bardelli A
Cancer Discov; 2014 Nov; 4(11):1269-80. PubMed ID: 25293556
[TBL] [Abstract][Full Text] [Related]
25. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
[TBL] [Abstract][Full Text] [Related]
26. Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer.
Grothey A
Oncology (Williston Park); 2006 Dec; 20(14 Suppl 10):21-8. PubMed ID: 17354514
[TBL] [Abstract][Full Text] [Related]
27. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?
Fakih M
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1471-80. PubMed ID: 18759698
[TBL] [Abstract][Full Text] [Related]
28. Role of panitumumab in the management of metastatic colorectal cancer.
Saif MW; Cohenuram M
Clin Colorectal Cancer; 2006 Jul; 6(2):118-24. PubMed ID: 16945167
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions.
Saif MW; Kaley K; Chu E; Copur MS
Clin Colorectal Cancer; 2010 Dec; 9(5):315-8. PubMed ID: 21208847
[TBL] [Abstract][Full Text] [Related]
30. [Biotherapy of cancer by anti-EGFR monoclonal antibody].
Wang J; Meng ZY; Fu ST; Dou GF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):1135-8. PubMed ID: 17956707
[TBL] [Abstract][Full Text] [Related]
31. Bevacizumab vs EGFR antibodies in metastatic colorectal cancer.
Venook AP
Clin Adv Hematol Oncol; 2015 Feb; 13(2):90-2. PubMed ID: 25774477
[No Abstract] [Full Text] [Related]
32. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer.
Saif MW; Syrigos KI; Hotchkiss S; Shanley J; Grasso J; Ferencz TM; Syrigos K; Shah MM
Cancer Chemother Pharmacol; 2009 Dec; 65(1):107-12. PubMed ID: 19415280
[TBL] [Abstract][Full Text] [Related]
33. [The current status of development of anti-EGFR antibodies].
Ura T
Gan To Kagaku Ryoho; 2010 May; 37(5):777-81. PubMed ID: 20495305
[TBL] [Abstract][Full Text] [Related]
34. Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials.
Bauer KA; Hammerman S; Rapoport B; Lacouture ME
Clin Colorectal Cancer; 2008 Sep; 7(5):309-14. PubMed ID: 18794062
[TBL] [Abstract][Full Text] [Related]
35. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
Eder J; Simonitsch-Klupp I; Trautinger F
Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
[TBL] [Abstract][Full Text] [Related]
36. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer.
Ouwerkerk J; Boers-Doets C
Eur J Oncol Nurs; 2010 Sep; 14(4):337-49. PubMed ID: 20580896
[TBL] [Abstract][Full Text] [Related]
37. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
Sartore-Bianchi A; Martini M; Molinari F; Veronese S; Nichelatti M; Artale S; Di Nicolantonio F; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
Cancer Res; 2009 Mar; 69(5):1851-7. PubMed ID: 19223544
[TBL] [Abstract][Full Text] [Related]
38. Where now for anti-EGF receptor therapies in colorectal cancer?
Shaw PH; Adams RA
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1543-53. PubMed ID: 21999128
[TBL] [Abstract][Full Text] [Related]
39. Targeted therapy in advanced colorectal cancer: more data, more questions.
Ochenduszko SL; Krzemieniecki K
Anticancer Drugs; 2010 Sep; 21(8):737-48. PubMed ID: 20631611
[TBL] [Abstract][Full Text] [Related]
40. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
Bouché O; Beretta GD; Alfonso PG; Geissler M
Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
